お知らせ • Feb 20
Bon Natural Life Limited Announces Development of Apple Bio-Electronic Mask Bon Natural Life Limited announced the successful development of a premium anti-aging facial mask incorporating apple polyphenols as its core active ingredient and integrated with AI-enabled flexible bio-electronic technology. Leveraging advanced transdermal delivery systems, this product integrates plant-derived active ingredients with intelligent flexible electronics, creating a next-generation skin care solution designed to be non-invasive, painless, and suitable for at-home use. Serving as the core natural active ingredient of this product, apple polyphenols are extracted from premium Apple pomace and contain polyphenolic compounds such as proanthocyanidins and quercetin. These compounds are widely studied for their antioxidant, anti-inflammatory, and photoprotective properties. Published research indicates that apple polyphenols may help inhibit collagen degradation, reduce UV-induced oxidative stress, and support melanin metabolism, contributing to visible improvements in skin firmness, brightness, and overall appearance. Powered by its AI-enabled flexible bio-Electronic platform, BON's mask combines flexible electronic materials with smart controlled-release technology to enhance transdermal penetration of the active ingredients. This approach is designed to address the absorption limitations typically associated with conventional topical skincare products. At present, the Company has completed sample development and preliminary internal performance evaluations of the AI-powered flexible bio-electronic mask incorporating apple polyphenols. Across key performance indicators -- including the appearance of fine lines, skin firmness, UV-related skin stress, and overall brightness -- the initial results have exceeded internal benchmarks. In the next phase, the Company plans to initiate expanded third-party clinical testing while advancing product finalization and optimizing large-scale manufacturing processes. According to industry data, the global anti-aging market has surpassed $100 billion, with premium transdermal delivery devices and advanced formulations representing one of the fastest-growing segments. By combining the functional properties of apple polyphenols with proprietary bio-electronic mask technology, BON believes it is well positioned to capture a first-mover advantage within this emerging premium segment. Reported Earnings • Jan 23
Full year 2025 earnings released: US$0.72 loss per share (vs US$4.37 profit in FY 2024) Full year 2025 results: US$0.72 loss per share (down from US$4.37 profit in FY 2024). Revenue: US$18.7m (down 22% from FY 2024). Net loss: US$1.99m (down US$2.41m from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 5 percentage points per year. お知らせ • Dec 11
Bon Natural Life Limited Unveils Kombucha-Inspired Product Bon Natural Life Limited announced the launch of a new health-focused kombucha-inspired product and a strategic collaboration with Shaanxi Qingshengyuan Health Industry Co. Ltd. The two parties entered into a non-exclusive strategic sales agreement. The term of the agreement is 24 months with a total contract value of $12 million. Pursuant to the agreement, Qingshengyuan will sell and distribute BON's high-tea-pigment products across Greater China. As a global innovator in tea-pigment ingredients, BON has observed growing consumer demand for tea-based products that are "more efficient, more pure, and more scientific." In response, the Company has developed a kombucha-inspired beverage produced from premium tea, sugar, and a Symbiotic Culture of Bacteria and Yeast ("SCOBY"). The product undergoes a controlled natural fermentation process that maintains the tea's fresh aroma, sweet aftertaste, and lightly effervescent texture, while enhancing the extraction and concentration of tea pigments. As a result, the beverage contains higher levels of tea pigments compared to similar products. Kombucha has become one of the fastest-growing functional beverage categories in recent years, driven by consumer interest in natural ingredients and perceived health benefits, particularly among younger consumers. BON's product is designed to align with these market trends and seeks to support category development through its ingredient-focused technology. Tea pigments are natural, water-soluble pigment complexes formed during the fermentation and oxidation of tea leaves and are considered key functional compounds in tea. Scientific literature indicates that tea pigments contribute to the color and clarity of tea infusions and have been the subject of research regarding potential biological properties, including antioxidant activity and other areas of scientific interest. As consumer preferences increasingly shift toward natural ingredients and as the functional food and beverage market expands, tea pigments are gaining broader commercial application as an alternative to synthetic additives. They are used in tea beverages, health-oriented consumer products, and other ingredient formulations within the food and beverage industry. Driven by these trends, the market for tea-pigment-based ingredients has continued to grow. Industry sources project that the overall market opportunity for tea-pigment applications could reach approximately $1 billion in the coming years. Valuation Update With 7 Day Price Move • Nov 18
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to US$1.61, the stock trades at a trailing P/E ratio of 10.1x. Average trailing P/E is 22x in the Chemicals industry in the US. Total loss to shareholders of 99% over the past three years. New Risk • Nov 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 11% per year over the past 5 years. High level of non-cash earnings (22% accrual ratio). Shareholders have been substantially diluted in the past year (over 22x increase in shares outstanding). Market cap is less than US$10m (US$7.10m market cap). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Profit margins are more than 30% lower than last year (2.8% net profit margin). Reported Earnings • Sep 30
First half 2025 earnings released First half 2025 results: Revenue: US$7.95m (down 22% from 1H 2024). Net income: US$169.2k (up US$179.7k from 1H 2024). Profit margin: 2.1% (up from net loss in 1H 2024). The move to profitability was driven by lower expenses. Valuation Update With 7 Day Price Move • Sep 10
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to US$1.92, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 27x in the Chemicals industry in the US. Total loss to shareholders of 100% over the past three years. お知らせ • Sep 03
Bon Natural Life Limited Announces Identification of Promising Weight-Managing Compounds from Tea Via AI-Powered New Drug R&D Platform Bon Natural Life Limited announced a groundbreaking identification of a class of natural polyphenolic compounds from a tea-derived product via its AI-Powered new drug research and development (R&D) platform. Preliminary tests demonstrate that these compounds exhibit significant activity in weight management, with key efficacy indicators outperforming current mainstream weight-managing drugs, injecting new momentum into global R&D of weight-managing drugs. With a worsening global obesity crisis, the weight-managing product market is experiencing robust growth. Data shows that the global weight-managing product market reached USD423.27 billion in 2024 and is projected to expand at a compound annual growth rate (CAGR) of 9.5% to USD601.26 billion by 20291. This market growth is primarily driven by the expanding obese population and rising awareness of healthy weight management. BON's AI platform integrates massive datasets of natural compounds and biomedical knowledge, leveraging advanced algorithms and innovative models. Its high-efficiency data analysis and screening capabilities have significantly shortened the component screening cycle traditionally associated with drug R&D, enabling the successful identification of these compounds with weight-loss potential. Preliminary animal studies showed significant weight reduction at specific compound doses, with no obvious adverse effects observed. Currently, the Company has established a dedicated team to advance follow-up work, including research into the compounds' mechanisms of action, structural optimization, expanded animal trials, and preparation for clinical trials. BON believes that the weight-managed product market represents a large-scale therapeutic area with substantial growth potential. If the Company successfully launches this new drug, it is well-positioned to capture a significant share of the global weight management therapeutics market - a development that would fundamentally and revolutionarily enhance the Company's investment value while delivering substantial returns to shareholders. Meanwhile, this R&D breakthrough has enabled the Company to efficiently and accurately identify weight-managing active molecules from natural tea-derived products. It also provides preliminary validation of the feasibility of BON's AI-based new drug R&D platform, helping the Company establish a highly efficient, new R&D model. This will lay a solid foundation for the Company's AI-driven R&D business focused on natural compound-based new drugs, accelerate the development of its AI-powered innovative drug research initiatives, and continue to create greater value for shareholders. New Risk • Aug 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Shareholders have been substantially diluted in the past year (over 22x increase in shares outstanding). Market cap is less than US$10m (US$4.88m market cap). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Profit margins are more than 30% lower than last year (1.8% net profit margin). お知らせ • Jul 30
Bon Natural Life Limited Launches AI-Powered New Drug Research and Development Bon Natural Life Limited announced the official launch of its AI-driven drug research and development (R&D) business. Leveraging its extensive library of natural compounds - many derived from Traditional Chinese Medicine (TCM) - the Company will apply artificial intelligence algorithms to identify high potential lead compounds, marking a significant evolution in its pharmaceutical strategy. A lead compound is a molecule with specific biological activity and a chemical structure that serves as a foundation for further development in drug discovery. Identifying such compounds through activity screening is a fundamental step in early-stage pharmaceutical R&D. With nearly two decades of experience in the research and development of natural products, BON has curated a robust library of biologically active compounds -- many with proven therapeutic value and high druggability. While previous R&D efforts were limited by traditional screening technologies, the integration of advanced AI-driven models is expected to significantly enhance the efficiency, speed, and success rate of BON's drug discovery process. The Company's new AI-driven platform is designed to quickly analyze and identify promising lead compounds for further optimization, supporting BON's broader goals of accelerating the development of innovative therapies rooted in natural product chemistry. Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to US$1.57, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 23x in the Chemicals industry in the US. Total loss to shareholders of 100% over the past three years. New Risk • Jul 07
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 22x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Shareholders have been substantially diluted in the past year (over 22x increase in shares outstanding). Market cap is less than US$10m (US$5.64m market cap). Minor Risk Profit margins are more than 30% lower than last year (1.8% net profit margin). お知らせ • Jun 03
Bon Natural Life Limited (NasdaqCM:BON) announces an Equity Buyback for $1 million worth of its shares. Bon Natural Life Limited (NasdaqCM:BON) announces a share repurchase program. Under the program, the company will repurchase up to $1 million worth of its shares. The program will be valid till the earlier of the one year anniversary of the execution date, the completion of all purchases contemplated by the Share Repurchase Program, termination by written notice of either party, any legal or regulatory restriction, a merger, acquisition or similar transaction of the Company, a liquidation, bankruptcy or reorganization of the Company, or failure by the Company to perform its obligations under the Agreement. お知らせ • May 15
BON Natural Life Limited Debuts Broccoli-Derived Sleep Wellness Line, Reshaping the Sleep Health Market Through Innovative Technology BON Natural Life Limited announced the launch of its sleep health product series. Developed using the proprietary "Glucoraphanin-Myrosinase" delivery system (patent-pending), the Company intends for this product to dramatically enhance the bio-activity (the extent to which something is absorbed and utilized by the body) of glucoraphanin, a vital bio-active compound in broccoli and will be launched under the Company's owned brand. Broccoli, a nutrient-rich superfood, contains glucoraphan in a key bio-active compound that undergoes metabolic conversion into sulforaphane in the human body. Sulforaphane has been linked to multiple health benefits, including anti-cancer properties, sleep regulation, neuro-protective effects, digestive health support, anti-inflammatory, antioxidant, and anti-aging effects. However, the enzymatic conversion of glucoraphanin into its active form, sulforaphane, is inefficient making it difficult for the body to fully utilize the health benefits of broccoli. This creates challenges for nutritional utilization and commercial application. The Company believes its patent-pending "Glucoraphan in-Myrosinase" represents an innovative biotechnological delivery system. By ensuring optimal enzymatic activation in the body, it achieves an advanced conversion efficiency of bio-active sulforaphane. This system is intended to help resolve fundamental bio-availability challenges. With its precision-driven design, easy usage, and consumer-friendly format, the Company believes this advancement holds transformative potentials through re-positioning glucoraphanin-sulforaphane in the health and wellness market, which will allow the Company to capitalize on potential revenue opportunities. お知らせ • May 03
Bon Natural Life Limited Announces Receipt of Nasdaq Delisting Notifications Bon Natural Life Limited announced that on April 29, 2025, the Company received a letter (the “Notification Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”), notifying the Company that it was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”), as the Company's closing bid price for its Class A ordinary shares, par value $0.001 per share was below $1.00 per share for the prior thirty (30) consecutive business days, which matter serves as a basis for delisting the Company’s securities from Nasdaq. Additionally, the Company’s securities had a closing bid of $0.10 or less for the last ten consecutive trading days, and accordingly, is subject to the provisions under Listing Rule 5810(c)(3)(A)(iii). This serves as an additional basis for delisting, and as such, the Company is not eligible for a compliance period. On May 1, 2025, the Company received an additional Notification Letter notifying the Company that the Staff has determined to delist the Company’s securities pursuant to their discretionary authority under Listing Rule 5101. The Staff’s determination was based on public interest concerns in relation to the Company’s March 2025 best efforts offering. The Company has filed a notice of appeal and requested a hearing before a Nasdaq Listing Qualifications Panel to review the Staff’s determination. The appeal will stay delisting of the Company’s securities pending the Panel’s decision. The Company will evaluate available options to regain compliance with the aforementioned Listing Rules. However, there are no assurances that the Company will be able to regain or maintain compliance or that any such appeal to the Panel will be successful, as applicable. お知らせ • Apr 09
Bon Natural Life Limited Announces Unlocking Broccoli's Nutritional Power: Advanced Delivery System for Glucoraphanin Activation Bon Natural Life Limited announced company innovation addresses nutritional critical challenges through a patent-pending Glucoraphanin-Myrosinase co-delivery system that significantly enhances the bio-activity of glucoraph anin, a key bio-active compound in Broccoli. Broccoli stands as a nutrient-rich super food containing glucoraphanin-the vegetable's key bio-active compound that could metabolically converted into sulforaphane within biological systems. Sulforaphane is associated with diverse bio-active properties ranging from anti-cancer, sleep improvement, neuroprotection, digestive system enhancement, anti-inflammatory, antioxidant, and anti-aging effects. However, this precursor molecule requires enzymatic conversion to sulforaphane, the active form that delivers these effects. This biological conversion process proves challenging and inefficient, posing a significant obstacle to effective nutritional utilization and commercial application. This breakthrough technology ensures optimal enzymatic activation within the body, achieving unprecedented conversion efficiency to bio-active sulforaphane. By industrially solving the fundamental bio-availability issue, company positioned to revolutionize functional food applications. Driven by the compound's diverse applications with significant potential in anti-tumor therapies, mental health support, and digestive health management, ongoing technological innovations--specifically those enhancing efficiency, usability, and user compliance-- are expected to unlock a multi-billion-dollar for sulforaphane across emerging sectors. お知らせ • Mar 20
Bon Natural Life Limited Announces Revolutionary Postbiotic Blood Sugar Solution Nears Patent Launch Bon Natural Life Limited announced a game-changing patent for a natural postbiotic ingredient designed to regulate blood sugar is gearing up for release. The Company has engineered a food-derived postbiotic formula for glycemic management, slated to hit shelves in the near term. When taken 10-30 minutes before meals, this breakthrough product delivers targeted control over post-meal glucose spikes, cutting blood sugar surges by 15-30% within the critical 1-3 hour window after eating-proven through rigorous testing. Early data shows its efficacy not only rivals but outperforms leading products already dominating the market. Beyond its precision, the formula boasts a unique edge: It's food-safe, easy to use, and designed for seamless integration into daily routines-key factors driving high user adherence. With these advantages, the solution is poised to disrupt the post-meal blood sugar control sector and capture significant market share. お知らせ • Mar 19
Bon Natural Life Limited has completed a Composite Units Offering in the amount of $11.999998 million. Bon Natural Life Limited has completed a Composite Units Offering in the amount of $11.999998 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 8,333,332
Price\Range: $1.44
Discount Per Security: $0.1152
Security Name: Pre-Funded Warrant
Security Type: Equity Warrant
Securities Offered: 8,333,332
Security Name: Series A Warrant
Security Type: Equity Warrant
Securities Offered: 8,333,332
Security Name: Series B Warrant
Security Type: Equity Warrant
Securities Offered: 8,333,332 Valuation Update With 7 Day Price Move • Mar 17
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to US$1.44, the stock trades at a trailing P/E ratio of 14.4x. Average trailing P/E is 21x in the Chemicals industry in the US. Total loss to shareholders of 96% over the past three years. New Risk • Mar 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 31% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (31% average weekly change). Shareholders have been substantially diluted in the past year (199% increase in shares outstanding). Market cap is less than US$10m (US$3.07m market cap). Minor Risk Profit margins are more than 30% lower than last year (1.8% net profit margin). Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to US$1.10, the stock trades at a trailing P/E ratio of 11x. Average trailing P/E is 21x in the Chemicals industry in the US. Total loss to shareholders of 97% over the past three years. Reported Earnings • Jan 28
Full year 2024 earnings released: EPS: US$0.17 (vs US$5.03 in FY 2023) Full year 2024 results: EPS: US$0.17 (down from US$5.03 in FY 2023). Revenue: US$23.8m (down 19% from FY 2023). Net income: US$417.7k (down 91% from FY 2023). Profit margin: 1.8% (down from 16% in FY 2023). The decrease in margin was driven by lower revenue. Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$1.38, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 23x in the Chemicals industry in the US. Total loss to shareholders of 96% over the past three years. Valuation Update With 7 Day Price Move • Dec 12
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to US$1.88, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 22x in the Chemicals industry in the US. Total loss to shareholders of 96% over the past three years. Reported Earnings • Nov 25
First half 2024 earnings released: US$0.008 loss per share (vs US$2.38 profit in 1H 2023) First half 2024 results: US$0.008 loss per share (down from US$2.38 profit in 1H 2023). Revenue: US$10.2m (down 28% from 1H 2023). Net loss: US$10.5k (down 100% from profit in 1H 2023). お知らせ • Nov 21
Bon Natural Life Limited has filed a Follow-on Equity Offering in the amount of $26 million. Bon Natural Life Limited has filed a Follow-on Equity Offering in the amount of $26 million.
Security Name: Ordinary Shares
Security Type: Common Stock Valuation Update With 7 Day Price Move • Oct 09
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to US$1.55, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 26x in the Chemicals industry in the US. Total loss to shareholders of 97% over the past three years. Reported Earnings • Oct 01
First half 2024 earnings released: US$0.008 loss per share (vs US$2.38 profit in 1H 2023) First half 2024 results: US$0.008 loss per share (down from US$2.38 profit in 1H 2023). Revenue: US$10.2m (down 28% from 1H 2023). Net loss: US$10.5k (down 100% from profit in 1H 2023). New Risk • Sep 29
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.6% Last year net profit margin: 19% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (256% increase in shares outstanding). Market cap is less than US$10m (US$7.15m market cap). Minor Risk Profit margins are more than 30% lower than last year (9.6% net profit margin). New Risk • Aug 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (256% increase in shares outstanding). Market cap is less than US$10m (US$7.22m market cap). Minor Risk Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Valuation Update With 7 Day Price Move • Jun 14
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to US$2.33, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 27x in the Chemicals industry in the US. Total loss to shareholders of 64% over the past year. Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to US$2.35, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 26x in the Chemicals industry in the US. Total loss to shareholders of 67% over the past year. New Risk • May 28
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (256% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$11.7m market cap). Valuation Update With 7 Day Price Move • May 22
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to US$3.12, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 26x in the Chemicals industry in the US. Total loss to shareholders of 52% over the past year. Board Change • Apr 30
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director James Burns is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. お知らせ • Feb 25
Bon Natural Life Limited, Annual General Meeting, Mar 09, 2024 Bon Natural Life Limited, Annual General Meeting, Mar 09, 2024, at 10:00 China Standard Time. Location: Room 601, Block C Gazelle Valley, No.69, Jinye Road Xi'an Shanxi Province China お知らせ • Jan 31
Bon Natural Life Limited announced delayed 20-F filing On 01/30/2024, Bon Natural Life Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC. お知らせ • Nov 30
Bon Natural Life Limited Announces Advancement in Sulforaphane Bon Natural Life Limited announced an achievement in converting glucoraphanin into sulforaphane, an active ingredient in broccoli extract. BON's dedicated R&D team has conducted extensive research, and completed the design of a new compound system, that, when introduced into the human body, integrates enzymes with broccoli extract, efficiently catalyzing glucoraphanin, a precursor, into sulforaphane. This technological advancement not only boosts the transformation rate and bioavailability of broccoli extract, but also reduces costs significantly, allowing for rapid market expansion. Additionally, it extends the shelf life of extract products, providing convenience to customers. Based on this new design, BON plans to launch a series of new health supplement products under the registered trademark: Broclife®? in areas of sleep improvement, digestive health, and immune health, seeking to meet the market demand for natural health products. Recognized for its numerous health benefits such as antioxidant, anti-aging, anti-inflammatory effects, immune enhancement, inhibition of cancer cell replication, support for digestive health, and promotion of the central nervous system, broccoli extract is a highly valuable ingredient. However, its application has been limited due to challenges related to formulation effectiveness and the high costs involved in production. Board Change • Nov 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director James Burns is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. お知らせ • Oct 13
Bon Natural Life Limited Announces Appointment of Jing Chen and Zhixiang Gao as Additional Independent Directors Bon Natural Life Limited Announced Appointment OF Jing Chen and Zhixiang Gao as additional independent directors on October 2, 2023. New Risk • Oct 06
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (25% accrual ratio). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (US$5.15m market cap). Minor Risk Share price has been volatile over the past 3 months (9.7% average weekly change). Reported Earnings • Sep 15
First half 2023 earnings released: EPS: US$0.24 (vs US$0.30 in 1H 2022) First half 2023 results: EPS: US$0.24 (down from US$0.30 in 1H 2022). Revenue: US$14.1m (up 3.4% from 1H 2022). Net income: US$2.12m (down 17% from 1H 2022). Profit margin: 15% (down from 19% in 1H 2022). The decrease in margin was driven by higher expenses. New Risk • Aug 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (37% accrual ratio). Market cap is less than US$10m (US$7.06m market cap). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (33% increase in shares outstanding). お知らせ • Jul 08
Bon Natural Life Limited Receives Nasdaq Notification Regarding Independent Board Requirement Bon Natural Life Limited announced that the Company received a letter (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on June 30, 2023, due to the resignations of Messrs. James Edward Burns, Lawrence W. Leighton, and Jeffrey J. Guzy from the Company’s Board of Directors and respective committee assignments effective May 19, June 26, and June 28, 2023, respectively, the Company no longer complies with Nasdaq’s majority independent board and independent audit, compensation, and nominating committee requirements as set forth in Listing Rule 5605. Under applicable Nasdaq rules, the Company has until no later than August 14, 2023 to submit a plan to regain compliance. If the plan is accepted, the Company may be granted an extension of up to 180 calendar days from the date of the Notification Letter to regain compliance. The Company is in the process of identifying and retaining new independent directors to serve on its board, and it intends to have a majority independent board reimplemented within the near future. お知らせ • Jun 22
Bon Natural Life Receives NASDAQ Notification Regarding Minimum Bid Deficiency On June 21, 2023, Bon Natural Life Limited announced that the company received a written notification (the ‘Notification Letter’) from the Nasdaq Stock Market LLC (‘Nasdaq’) on June 12, 2023, notifying the Company that it is not in compliance with the minimum bid price requirement set in Nasdaq Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of USD 1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s ordinary shares for the 30 consecutive business days from April 28, 2023 to June 12, 2023, the Company no longer meets the minimum bid price requirement. The Notification Letter does not impact the Company’s listing on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until December 11, 2023, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s ordinary shares must have a closing bid price of at least USD 1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by December 11, 2023, the Company may be eligible for additional time to regain compliance or may face delisting. お知らせ • Jun 03
Bon Natural Life Limited Launches Three New Cruciferous Vegetable-Based Powder Drinks Bon Natural Life Limited announced the launch of three powder drinks to its cruciferous vegetable-based health supplement series. The new powder drinks include: broccoli seed caffeine powder drink, broccoli seed coconut powder drink, and broccoli seed green tea powder drink. Thoughtfully formulated, the combination of broccoli seed extract and BON's proprietary prebiotic stachyose can help regulate microbiome health to improve one's immune system and overall health. お知らせ • Feb 08
Bon Natural Life Limited to Report Fiscal Year 2022 Results on Feb 10, 2023 Bon Natural Life Limited announced that they will report fiscal year 2022 results at 9:30 AM, US Eastern Standard Time on Feb 10, 2023 お知らせ • Feb 01
Bon Natural Life Limited announced delayed 20-F filing On 01/31/2023, Bon Natural Life Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC. Valuation Update With 7 Day Price Move • Jan 23
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$1.17, the stock trades at a trailing P/E ratio of 2.7x. Average forward P/E is 14x in the Chemicals industry in the US. Total loss to shareholders of 66% over the past year. Valuation Update With 7 Day Price Move • Jan 05
Investor sentiment improved over the past week After last week's 21% share price gain to US$1.16, the stock trades at a trailing P/E ratio of 2x. Average forward P/E is 12x in the Chemicals industry in the US. Total loss to shareholders of 72% over the past year. Valuation Update With 7 Day Price Move • Nov 28
Investor sentiment improved over the past week After last week's 23% share price gain to US$1.18, the stock trades at a trailing P/E ratio of 2.1x. Average forward P/E is 12x in the Chemicals industry in the US. Total loss to shareholders of 78% over the past year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Lawrence Leighton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Nov 01
Investor sentiment deteriorated over the past week After last week's 16% share price decline to US$1.34, the stock trades at a trailing P/E ratio of 2.3x. Average forward P/E is 13x in the Chemicals industry in the US. Total loss to shareholders of 78% over the past year. Valuation Update With 7 Day Price Move • Oct 10
Investor sentiment deteriorated over the past week After last week's 19% share price decline to US$1.82, the stock trades at a trailing P/E ratio of 3.2x. Average forward P/E is 12x in the Chemicals industry in the US. Total loss to shareholders of 72% over the past year. お知らせ • Oct 01
Bon Natural Life Limited Provides Update on Its Expansion Project Bon Natural Life Limited announced that there will be a delay to the initial production target of Fourth Quarter 2022 for its third production site – Yumen Plant to May 2023. BON has completed the building structure of the facility in May 2022 as scheduled and expected to commence around September this year. However, against the backdrop of the strict COVID-19 control protocol and prevention policies in China, the lingering logistic disruption, material and labor shortage, and domestic travel restriction have caused delay in Yumen Plant's interior outfitting, site inspection, and equipment installation. Valuation Update With 7 Day Price Move • Sep 14
Investor sentiment improved over the past week After last week's 16% share price gain to US$2.15, the stock trades at a trailing P/E ratio of 3.7x. Average forward P/E is 12x in the Chemicals industry in the US. Total loss to shareholders of 80% over the past year. Board Change • Sep 03
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Lawrence Leighton was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment improved over the past week After last week's 38% share price gain to US$2.77, the stock trades at a trailing P/E ratio of 4.8x. Average forward P/E is 13x in the Chemicals industry in the US. Total loss to shareholders of 75% over the past year. Valuation Update With 7 Day Price Move • Aug 08
Investor sentiment improved over the past week After last week's 20% share price gain to US$2.06, the stock trades at a trailing P/E ratio of 3.6x. Average forward P/E is 12x in the Chemicals industry in the US. Total loss to shareholders of 84% over the past year. Reported Earnings • Aug 02
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down US$2.31m from profit in 1H 2021). Profit margin: (down from 20% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 48%, compared to a 13% growth forecast for the industry in the US. お知らせ • Jul 29
Bon Natural Life Limited to Report Q2, 2022 Results on Aug 01, 2022 Bon Natural Life Limited announced that they will report Q2, 2022 results at 9:30 AM, US Eastern Standard Time on Aug 01, 2022 Valuation Update With 7 Day Price Move • Jul 01
Investor sentiment deteriorated over the past week After last week's 17% share price decline to US$2.53, the stock trades at a trailing P/E ratio of 4.6x. Average forward P/E is 14x in the Chemicals industry in the US. Total loss to shareholders of 69% over the past year. お知らせ • Jul 01
Bon Natural Life Limited Announces Board Changes Bon Natural Life Limited announced the appointment of Jeffrey Guzy, as a new independent Director to its Board of Directors and as Chair of the Audit Committee, both effective June 28, 2022. Effective June 27, 2022, Mr. Christopher Constable resigned as a director of the Company for personal reasons and stepped down as a member and chairman of the audit committee of the Board. The resignation of Mr. Constable did not result from any dispute or disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices. Mr. Jeffrey Guzy has had key executive positions at several large international companies, including Loral Space, Sprint International, Verizon and IBM. Mr. Guzy is a private investor and advisor to Aprize Satellite and to several other hi-tech companies. Mr. Guzy has an MBA in Strategic Planning and Management from The Wharton School of the University of Pennsylvania, an M.S. in Systems Engineering from the University of Pennsylvania; a B.S. in Electrical Engineering from Penn State University; and a Certificate in Theology from Georgetown University. Mr. Guzy's extensive business and financial oversight experience led to the conclusion that he should serve as a director and qualify as an audit committee financial expert. お知らせ • Jun 17
Bon Natural Life Limited Introduces New Powder Drink for Anti-H. Pylori and Digestive Health Bon Natural Life Limited announced that it has launched a new cruciferous vegetable based probiotic powder drink that could potentially inhibit the proliferation of Helicobacter pylori and help regulate the digestive system. The powder drink is the first proprietary product of BON's cruciferous vegetable based health supplement series. By formulating three different kinds of patented probiotics with sulforaphane, a chemical compound extracted from broccoli, and fucoidan, a compound extracted from seaweed, BON is able to leverage its innovative technology to develop a product with potential anti-pylori effect. Additionally, this powder drink could also regulate and improve one's overall microbiome and digestive health. Valuation Update With 7 Day Price Move • May 27
Investor sentiment deteriorated over the past week After last week's 18% share price decline to US$3.77, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 17x in the Chemicals industry in the US. Valuation Update With 7 Day Price Move • May 03
Investor sentiment improved over the past week After last week's 46% share price gain to US$5.62, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 19x in the Chemicals industry in the US. お知らせ • Apr 22
Bon Natural Life Limited Adds New Multi-Functional Health Supplements to Product Line Bon Natural Life Limited announced that it has successfully developed new nutraceutical compounds – Glucoraphanin ("GF") and Sulforaphane ("SFN"), both of which are compounds extracted from cruciferous vegetables that could potentially provide immunity support and improve certain other regulatory health functions. The Company plans to launch GF and SFN based consumer products in the next six months. According to a recent study led by John Hopkins University and published by Nature, both compounds are shown potential effect in inhibiting the infection of SARS-CoV-2, including Delta and Omicron (Source: Ordonez, A.A., Bullen, C.K., Villabona-Rueda, A.F. et al. Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice. Commun Biol 5, 242 (2022).). BON has achieved cutting-edge technological breakthroughs in developing such products, including developing a proprietary GF separation platform and various GF based health supplement consumer products with long shelf life and building a high-efficiency SFN production line with proprietary technology to reduce gastrointestinal irritation. In addition, BON also plants the highest concentration cruciferous vegetables farm to improve the large-scale production. The Company plans to introduce the following health supplement products within the next six months via multiple sales channels, including direct sales to pharmacies and enterprise clients, e-commerce platforms and distributors. These products likely include: Immune system booster in soft gel capsules; Digestive health booster in soft gel capsules; Weight loss management products; Sleep aid products for mid-aged and elderly. Valuation Update With 7 Day Price Move • Apr 06
Investor sentiment deteriorated over the past week After last week's 16% share price decline to US$3.17, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 19x in the Chemicals industry in the US. Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment improved over the past week After last week's 21% share price gain to US$4.76, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 21x in the Chemicals industry in the US. Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improved over the past week After last week's 24% share price gain to US$4.12, the stock trades at a trailing P/E ratio of 7.5x. Average trailing P/E is 21x in the Chemicals industry in the US. Reported Earnings • Feb 03
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: US$0.69 (up from US$0.58 in FY 2020). Revenue: US$25.5m (up 40% from FY 2020). Net income: US$4.59m (up 52% from FY 2020). Profit margin: 18% (up from 17% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. お知らせ • Jan 30
Bon Natural Life Limited to Report Fiscal Year 2021 Results on Jan 31, 2022 Bon Natural Life Limited announced that they will report fiscal year 2021 results Pre-Market on Jan 31, 2022 Valuation Update With 7 Day Price Move • Jan 10
Investor sentiment deteriorated over the past week After last week's 18% share price decline to US$3.66, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 22x in the Chemicals industry in the US. Valuation Update With 7 Day Price Move • Nov 22
Investor sentiment deteriorated over the past week After last week's 18% share price decline to US$5.25, the stock trades at a trailing P/E ratio of 11x. Average trailing P/E is 23x in the Chemicals industry in the US. Valuation Update With 7 Day Price Move • Oct 28
Investor sentiment deteriorated over the past week After last week's 16% share price decline to US$6.18, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 24x in the Chemicals industry in the US. Valuation Update With 7 Day Price Move • Oct 13
Investor sentiment deteriorated over the past week After last week's 15% share price decline to US$6.20, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 23x in the Chemicals industry in the US. Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment deteriorated over the past week After last week's 19% share price decline to US$8.10, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 23x in the Chemicals industry in the US. Valuation Update With 7 Day Price Move • Sep 09
Investor sentiment improved over the past week After last week's 21% share price gain to US$11.90, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 22x in the Chemicals industry in the US. Reported Earnings • Aug 21
First half 2021 earnings released: EPS US$0.40 (vs US$0.30 in 1H 2020) The company reported a solid first half result with improved earnings and revenues, although profit margins were weaker. First half 2021 results: Revenue: US$11.7m (up 64% from 1H 2020). Net income: US$2.31m (up 51% from 1H 2020). Profit margin: 20% (down from 21% in 1H 2020). The decrease in margin was driven by higher expenses.